Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy
Links shared publicly online about this topic.
- 788total visits
Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy
Arena Pharmaceuticals, Inc. announced today results from a Phase 1 clinical trial of APD916, a novel drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy with cataplexy.
View full resource at news-medical.net
Tags: Sleep Disorder, Narcolepsy, Drug, Pharma, Phase 1 Clinical Trial, Clinical Trial
Most Recently Shared on October 20, 2010 at 1:35 pm By:
Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy: Arena Pharmaceuticals, Inc. ... http://bit.ly/9PqNAy
Advertisement
